title: New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.
abstract: The therapeutic landscape for multiple sclerosis (MS) is rapidly changing. Currently, there are eight FDA approved disease modifying therapies for MS including: IFN-β-1a (Avonex, Rebif), IFN-β-1b (Betaseron, Extavia), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), natalizumab (Tysabri), and fingolimod (Gilenya). This review will highlight the experience to date and key clinical trials of the newest FDA approved agents, natalizumab and fingolimod. It will also review available efficacy and safety data on several promising therapies under active investigation including four monoclonal antibody therapies: alemtuzumab, daclizumab, ocrelizumab and ofatumumab and three oral agents: BG12, laquinimod, and teriflunomide. To conclude, we will discuss where each of these new therapies may best fit into treatment algorithms.
authors: The Ohio State University Medical Center, Department of Neurology, Division of Neuro-immunology, Columbus, Ohio.
authors: J
authors: J
authors: Nicholas
authors: B
authors: B
authors: Morgan-Followell
authors: D
authors: D
authors: Pitt
authors: M K
authors: MK
authors: Racke
authors: A
authors: A
authors: Boster
keywords: BG12; alemtuzumab; daclizumab; fingolimod; laquinimod, and teriflunomide; multiple sclerosis; natalizumab; ocrelizumab; ofatumumab; treatment
references: Lancet. 1999 Nov 13;354(9191):1691-5
references: 10568572
references: Ann Neurol. 2009 Sep;66(3):403-6
references: 19798640
references: N Engl J Med. 2007 Jun 21;356(25):2622-9
references: 17582072
references: Ann Neurol. 2006 May;59(5):743-7
references: 16634029
references: Neurology. 2009 Mar 3;72(9):806-12
references: 19255407
references: Lancet Neurol. 2010 Apr;9(4):425-37
references: 20298966
references: Lancet Neurol. 2010 Apr;9(4):381-90
references: 20163990
references: Neurology. 2011 Aug 9;77(6):573-9
references: 21795656
references: N Engl J Med. 2005 Jul 28;353(4):375-81
references: 15947078
references: Lancet. 2011 Nov 19;378(9805):1779-87
references: 22047971
references: Neurology. 2005 Mar 22;64(6):987-91
references: 15781813
references: Nat Rev Drug Discov. 2010 Oct;9(10):767-74
references: 20811384
references: Lancet Neurol. 2007 May;6(5):431-41
references: 17434098
references: Ann Rheum Dis. 2000 Nov;59 Suppl 1:i109-14
references: 11053100
references: Lancet Neurol. 2011 Aug;10(8):745-58
references: 21777829
references: Lancet. 2008 Oct 25;372(9648):1463-72
references: 18970976
references: Ann Neurol. 2011 May;69(5):759-77
references: 21520239
references: Arthritis Rheum. 2012 Feb;64(2):350-9
references: 21905001
references: N Engl J Med. 2006 Mar 2;354(9):911-23
references: 16510745
references: Ann Neurol. 2010 Sep;68(3):295-303
references: 20737510
references: Mult Scler. 2010 Nov;16(11):1360-6
references: 20834039
references: Brain. 1996 Dec;119 ( Pt 6):2009-19
references: 9010005
references: Drug Metab Dispos. 2005 Jun;33(6):866-72
references: 15764719
references: N Engl J Med. 2005 Jul 28;353(4):362-8
references: 15947080
references: Int MS J. 2009 Sep;16(3):77-81
references: 19878629
references: J Neurol Sci. 2011 Jul 15;306(1-2):173-9
references: 21429524
references: Arch Neurol. 2009 Apr;66(4):483-9
references: 19364933
references: N Engl J Med. 2005 Jul 28;353(4):369-74
references: 15947079
references: J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):55-60
references: 21865211
references: N Engl J Med. 2008 Oct 23;359(17):1786-801
references: 18946064
references: N Engl J Med. 2003 Jan 2;348(1):15-23
references: 12510038
references: N Engl J Med. 2010 Feb 4;362(5):402-15
references: 20089954
references: Clin Immunol. 2012 Jan;142(1):25-30
references: 21550857
references: Neurology. 2011 May 31;76(22):1858-65
references: 21543733
references: Neurodegener Dis. 2008;5(1):27-31
references: 18075272
references: Lancet. 2008 Jun 21;371(9630):2085-92
references: 18572078
references: N Engl J Med. 2006 Mar 2;354(9):899-910
references: 16510744
references: Mult Scler. 2011 Aug;17(8):958-63
references: 21613333
references: Neurology. 2011 Sep 13;77(11):1061-7
references: 21832229
references: Eur J Neurol. 2006 Jun;13(6):604-10
references: 16796584
references: Neuropsychiatr Dis Treat. 2009;5:333-40
references: 19557143
references: Br J Dermatol. 1999 Sep;141(3):424-9
references: 10584060
references: J Exp Med. 2011 Oct 24;208(11):2291-303
references: 21987655
references: Lancet Neurol. 2011 Jun;10(6):520-9
references: 21571593
references: J Neurol. 2009 Jan;256(1):89-103
references: 19169851
references: Nat Rev Drug Discov. 2010 Feb;9(2):101-2
references: 20118960
references: Curr Neurol Neurosci Rep. 2009 Sep;9(5):341-2
references: 19664362
references: Ann Neurol. 2011 Jun;69(6):1060-1; author reply 1061-2
references: 21328606
references: Neurology. 2009 Feb 3;72(5):396-401
references: 18987352
references: Br J Clin Pharmacol. 2004 Oct;58(4):429-32
references: 15373936
references: J Neuroimmunol. 2010 Oct 8;227(1-2):133-43
references: 20684995
references: N Engl J Med. 2011 Oct 6;365(14):1293-303
references: 21991951
references: Mult Scler. 2011 Apr;17(4):490-4
references: 21135017
references: Arch Neurol. 2008 Nov;65(11):1538-9
references: 19001176
references: N Engl J Med. 2010 Feb 4;362(5):387-401
references: 20089952
references: Curr Opin Rheumatol. 2011 May;23(3):282-7
references: 21427581
references: J Neurol. 2011 Oct;258(10):1805-11
references: 21625938
references: Ann Pharmacother. 2011 Oct;45(10):1248-55
references: 21896924
references: Clin Exp Immunol. 2006 Jul;145(1):101-7
references: 16792679
references: Cochrane Database Syst Rev. 2010 Jun 16;(6):CD008127
references: 20556791